MZ1 was the first PROTAC drug developed, with active ligands at both ends linked to the ubiquitin ligase von Hippel–Lindau (VHL) and the bromodomain and extra-terminal domain family protein bromodomain-containing protein 4 (BRD4) for cancer treatment (Fig. 4b) [78]. Here, BRD4 is linked to cancer.